Newsroom

Please note that the Company does not update, correct or revise news releases after they have been issued. For the most current information about the Company, please refer to the most recent releases.

06/08/2021, Tuesday

Bausch + Lomb and Lochan Enter Into Agreement to Develop the Next-Generation of eyeTELLIGENCE™ Clinical Decision Support Software

06/02/2021, Wednesday

Bausch + Lomb and Clearside Biomedical Announce U.S. FDA Filing Acceptance For XIPERE™ (Triamcinolone Acetonide Suprachoroidal Injectable Suspension)

06/01/2021, Tuesday

Bausch + Lomb and Prevent Blindness Launch Educational Campaign During Cataract Awareness Month

05/11/2021, Tuesday

New National Eye Institute Data Shows AREDS2 Nutrient Formula Continues to Reduce the Risk of Moderate to Advanced Age-Related Macular Degeneration Progression

04/29/2021, Thursday

Bausch + Lomb Will Present New Scientific Data and Analyses on Products and Pipeline Programs During the Association for Research in Vision and Ophthalmology Meeting

04/29/2021, Thursday

Bausch + Lomb Will Present New Scientific Data and Analyses on Products and Pipeline Programs During the Association for Research in Vision and Ophthalmology Meeting

04/13/2021, Tuesday

Bausch + Lomb Announces Statistically Significant Topline Results from the First Phase 3 Trial of Nov03 (Perfluorohexyloctane) in Dry Eye Disease Associated with Meibomian Gland Dysfunction

04/07/2021, Wednesday

FDA Approves Bausch + Lomb ClearVisc™ Dispersive Ophthalmic Viscosurgical Device (OVD)

02/23/2021, Tuesday

Bausch + Lomb Launches Alaway® Preservative Free Antihistamine Eye Drops

02/01/2021, Monday

Prevent Blindness and Bausch + Lomb to Launch Year-Long Video Series to Raise Awareness of Age-Related Macular Degeneration (AMD)

01/20/2021, Wednesday

Bausch + Lomb Announces Scientific Data on Bausch + Lomb INFUSE™ Silicone Hydrogel Daily Disposable Contact Lenses to be Presented at the Virtual Global Specialty Lens Symposium

01/19/2021, Tuesday

Bausch + Lomb Completes Enrollment of First Phase 3 Study For NOV03 (perfluorohexyloctane)